Literature DB >> 2747645

Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.

J H Axelrod1, R Reich, R Miskin.   

Abstract

The gene transfer technique was used to examine the role of plasminogen activator (PA) in the invasive and metastatic behavior of tumorigenic cells. H-ras-transformed NIH 3T3 clonal cells producing a very low level of PA were generated and further transfected with an expression plasmid containing a cDNA sequence encoding either the urokinase-type or the tissue-type human PA. Compared with the parental transformed cells, clonal cells expressing high levels of both types of recombinant PA invaded more rapidly through a basement membrane reconstituted in vitro. Furthermore, cells expressing high levels of recombinant urokinase-type PA also caused a higher incidence of pulmonary metastatic lesions after intravenous injection into nude mice. Both activities were reduced by the serine proteinase inhibitor EACA; invasion was also suppressed by antibodies blocking the activity of human PAs and by the synthetic collagenase inhibitor SC-44463. These findings provide direct genetic evidence for a causal role of PA in invasive and metastatic activities.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2747645      PMCID: PMC363007          DOI: 10.1128/mcb.9.5.2133-2141.1989

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

Review 1.  Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.

Authors:  L A Liotta
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

Review 2.  Plasminogen activators, tissue degradation, and cancer.

Authors:  K Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

Review 3.  Methods in metastasis research. A critical review.

Authors:  B Hagmar; W Ryd; L J Erkell
Journal:  Invasion Metastasis       Date:  1983

Review 4.  Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies.

Authors:  V Schirrmacher
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

5.  Proteinases and proteinase inhibition by cytotoxic and antimetastatic drugs in transplantable solid metastasizing tumors in mice.

Authors:  T Giraldi; G Sava; L Perissin; S Zorzet
Journal:  Anticancer Res       Date:  1985 Jul-Aug       Impact factor: 2.480

6.  Tumorigenic and metastatic properties of "normal" and ras-transfected NIH/3T3 cells.

Authors:  R G Greig; T P Koestler; D L Trainer; S P Corwin; L Miles; T Kline; R Sweet; S Yokoyama; G Poste
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

7.  Expression of the metastatic phenotype in cells transfected with human metastatic tumor DNA.

Authors:  S C Bernstein; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

8.  NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice.

Authors:  U P Thorgeirsson; T Turpeenniemi-Hujanen; J E Williams; E H Westin; C A Heilman; J E Talmadge; L A Liotta
Journal:  Mol Cell Biol       Date:  1985-01       Impact factor: 4.272

9.  Multiple forms of plasminogen activator in human breast tumors.

Authors:  P O'Grady; H R Lijnen; M J Duffy
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

10.  Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.

Authors:  L Skriver; L I Larsson; V Kielberg; L S Nielsen; P B Andresen; P Kristensen; K Danø
Journal:  J Cell Biol       Date:  1984-08       Impact factor: 10.539

View more
  34 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

2.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

Review 3.  The role of proteolytic enzymes in cancer invasion and metastasis.

Authors:  M J Duffy
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

4.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

Review 5.  Tumoral invasion in the central nervous system.

Authors:  Y A De Clerck; H Shimada; I Gonzalez-Gomez; C Raffel
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity.

Authors:  A Isacchi; M Statuto; R Chiesa; L Bergonzoni; M Rusnati; P Sarmientos; G Ragnotti; M Presta
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

7.  H-Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathway.

Authors:  Yunge Zhao; Aizhen Xiao; Charles G Dipierro; Rana Abdel-Fattah; Samson Amos; Gerard T Redpath; Joan E Carpenter; Russell O Pieper; Isa M Hussaini
Journal:  Glia       Date:  2008-06       Impact factor: 7.452

8.  Overexpression of the alpha-type protein kinase (PK) C in LLC-PK1 cells does not lead to a proportional increase in the induction of two 12-O-tetradecanoylphorbol-13-acetate-inducible genes.

Authors:  M Wartmann; D A Jans; P J Parker; Y Nagamine; B A Hemmings; S Jaken; U Eppenberger; D Fabbro
Journal:  Cell Regul       Date:  1991-06

9.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays.

Authors:  S N Bae; G Arand; H Azzam; P Pavasant; J Torri; T L Frandsen; E W Thompson
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.